Cancer NetworkOriginal article
<![CDATA[BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma]]>
Data ReadoutpositiveBCMA CAR T-cell therapyTeclistamabPositive
AI Analysis
Summary
Retrospective data showed BCMA CAR T-cell therapy improved overall survival compared to teclistamab in multiple myeloma patients, though immune-related toxicities were more common with the CAR T approach.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
BCMA CAR T-cell therapy showed improved overall survival compared to teclistamab in retrospective data analysis
Importance:6/10
Sentiment:
0.60
multiple myelomaCAR T-cellBCMAoverall survivalcomparative dataimmune-related toxicity
Read the original article
Published by Cancer Network on June 3, 2026 4:30 PM